<DOC>
	<DOCNO>NCT02173171</DOCNO>
	<brief_summary>A Registry Study Evaluate Survival Long-Term Safety Subjects With Melanoma Who Previously Received Talimogene Laherparepvec</brief_summary>
	<brief_title>Registry Study Talimogene Laherparepvec</brief_title>
	<detailed_description>A Registry Study Evaluate Survival Long-Term Safety Subjects With Melanoma Who Previously Received least 1 dose Talimogene Laherparepvec . FU occur q3m .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>All subject must provide informed consent prior initiation study activity . All subject must receive least one dose talimogene laherparepvec Amgen BioVEXsponsored clinical trial must permanently discontinue treatment trial . Subjects currently receive plan receive talimogene laherparepvec next 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Melanoma</keyword>
</DOC>